Clinical trial
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
NCT06179069
Study timeline
Study start (actual)2024-01-23Date precision: day
Registry last updated2026-08-21
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
SCLCunresolved
Interventions
ZL-1310DRUG
AtezolizumabDRUG · verified · RxNorm: atezolizumab
CarboplatinDRUG · verified · RxNorm: carboplatin
Sponsors & collaborators
Zai Lab (Shanghai) Co., Ltd.lead sponsor
Zai Lab (US) LLCcollaborator
Mapped research locations
MadridMadrid, Spain2MadridSpain1BarcelonaSpain1ClevelandOhio, United States1PittsburghPennsylvania, United States1DurhamNorth Carolina, United States1BeijingBeijing Municipality, China1DetroitMichigan, United States1ShanghaiShanghai Municipality, China1New HavenConnecticut, United States1GuangzhouGuangdong, China1CharlestonSouth Carolina, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06179069 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.